All In Biotech

Drug Trial Radar · NCT07706673

ESCUDDO Long Term Follow Up

A Scientific Evaluation of One or Two Doses of a Vaccine Against Human Papillomavirus: Long Term Follow Up of Gardasil9 Recipients in the ESCUDDO Study ("Estudio de Comparación de Una y Dos Dosis de Vacunas Contra el Virus de Papiloma Humano (VPH)")

Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Enrolling by invitationPivotal-lookingRandomized with 13,700 participants. This is a heuristic, not a regulatory label.

Status

Enrolling by invitation

Enrollment

13,700

Planned (sponsor's estimate)

Start

Aug 11, 2026

Primary completion

Oct 1, 2030

Study completion Jan 15, 2031

Sponsor

Sponsor type
NIH
Collaborators
Merck Sharp and Dohme LLC
First posted
Jul 16, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
Female only, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This phase IV trial evaluates the long term protection provided by either one or two doses of the 9v human papillomavirus (HPV) vaccine for participants who were part of the ESCUDDO study.

Conditions

  • Human Papillomavirus Infection
  • Human Papillomavirus-Related Malignant Neoplasm

Interventions

  • Diphtheria Toxoid/Tetanus Toxoid/Acellular Pertussis Vaccine AdsorbedBiological

    Given IM in ESCUDDO (NCT03180034)

  • Recombinant Human Papillomavirus Nonavalent VaccineBiological

    Given intramuscularly (IM) in ESCUDDO (NCT03180034)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Comparison of incident persistent human papillomavirus (HPV) infection related to vaccine types observed during long-term follow-up study (LFTU) and the combined ESCUDDO base and LTFU studies; in recipients of single dose and 2 doses of the 9vHPV vaccineTime frame: 7 to 10 years after first HPV vaccination
  2. Comparison of cumulative persistent HPV infection (Base Study + LTFU)Time frame: 1 to 10 years after first HPV vaccination

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Agencia Costarricense de Investigaciones Biomédicas (ACIB)

    Liberia, Guanacaste Province, Costa Rica

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.